LAVA Therapeutics N.V. (LVTX)
1.16
-0.02 (-1.69%)
At close: Apr 04, 2025, 3:33 PM
-1.69% (1D)
| Bid | 0.84 |
| Market Cap | 30.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -1.23 |
| Forward PE | -0.69 |
| Analyst | Hold |
| Ask | 1.42 |
| Volume | 95,817 |
| Avg. Volume (20D) | 421,281 |
| Open | 1.15 |
| Previous Close | 1.18 |
| Day's Range | 1.12 - 1.19 |
| 52-Week Range | 0.85 - 3.57 |
| Beta | 0.45 |
About LVTX
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for b...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 34
Stock Exchange NASDAQ
Ticker Symbol LVTX
Website https://www.lavatherapeutics.com
Analyst Forecast
According to 3 analyst ratings, the average rating for LVTX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 72.41% from the latest price.
Stock ForecastsEarnings Surprise
LAVA Therapeutics has released their quartely earnings
on Mar 28, 2025:
1 month ago
+42.55%
Lava Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
3 months ago
-23.56%
LAVA Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results.
